Barrett's oesophagus patients attending hospital: Baseline clinical, patient history and quality of life data from BOSS and AspECT by Love, S, Reilly, G, Roberts, C, Wise, A, Moayyedi, P, Foy, C, Stokes, C, De Caestecker, J, Attwood, S, Watson, R, Ang, Y, Bhandari, P, Old, O, Hapeshi, J, Penman, I, Rodgers, C, Edwards, C, Monk, D, Ragunath, K, Morris, D, Johnston, D, Barr, H, Jankowski, J

Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: efficacy and safety in the phase III randomized factorial AspECT Trial by Jankowski, JJ, de Caestecker, JDC, Love, SBL, Reilly, G, Ang, YA, Ragunath, KR, Tucker, AT, Penman, IP, Rodgers, CR, Neale, JN, Roffe, ER, Brooks, CB, Attwood, SA, Morris, DM, Harrison, RH, Bhandari, PB, Watson, PW, Sanders, SS, Barr, HB, Maoayyedi, PM, AspECT Team

“…Esophageal adenocarcinoma (EA) is the sixth most common cause of global cancer death. We rely on endoscopy screening to identify and monitor patients with Barrett’s esophagus (BE) and find neoplastic lesions early enough to manage their EA. …”